Efficacy of surotomycin in an in vitro gut model of Clostridium difficile infection

Successful treatment of simulated Clostridium difficile infection in a human gut model by fidaxomicin first line and after vancomycin or metronidazole failure

(2013) C. H. Chilton et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Fidaxomicin Versus Vancomycin for Clostridium difficile Infection: Meta-analysis of Pivotal Randomized Controlled Trials

(2012) Derrick W. Crook et al.   CLINICAL INFECTIOUS DISEASES

Effectiveness of a short (4 day) course of oritavancin in the treatment of simulated Clostridium difficile infection using a human gut model

(2012) C. H. Chilton et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Co-amoxiclav induces proliferation and cytotoxin production of Clostridium difficile ribotype 027 in a human gut model

(2012) C. H. Chilton et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Clinical and economic burden of Clostridium difficile infection in Europe: a systematic review of healthcare-facility-acquired infection

(2012) P.N. Wiegand et al.   JOURNAL OF HOSPITAL INFECTION

Economic healthcare costs of Clostridium difficile infection: a systematic review

(2010) S.S. Ghantoji et al.   JOURNAL OF HOSPITAL INFECTION

Tolevamer Is Not Efficacious in the Neutralization of Cytotoxin in a Human Gut Model of Clostridium difficile Infection

(2009) S. D. Baines et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Comparison of Clinical and Microbiological Response to Treatment ofClostridium difficile–Associated Disease with Metronidazole and Vancomycin

(2008) Wafa N. Al‐Nassir et al.   CLINICAL INFECTIOUS DISEASES

Emergence of reduced susceptibility to metronidazole in Clostridium difficile

(2008) S. D. Baines et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Comparison of oritavancin versus vancomycin as treatments for clindamycin-induced Clostridium difficile PCR ribotype 027 infection in a human gut model

(2008) S. D. Baines et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY